{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:47:00Z","timestamp":1789732020981,"version":"4.0.1"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10741-019-09806-0","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T12:02:52Z","timestamp":1560772972000},"page":"743-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies"],"prefix":"10.1007","volume":"24","author":[{"given":"Zijun","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cris","family":"dos Remedios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-560X","authenticated-orcid":false,"given":"Sean","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"issue":"8","key":"9806_CR1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 18(8):891\u2013975","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"9806_CR2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12471-016-0810-1","volume":"24","author":"L van Heerebeek","year":"2016","unstructured":"van Heerebeek L, Paulus WJ (2016) Understanding heart failure with preserved ejection fraction: where are we today? Neth Hear J 24(4):227\u2013236","journal-title":"Neth Hear J"},{"issue":"1","key":"9806_CR3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1574884708666131117125508","volume":"11","author":"BN Reed","year":"2015","unstructured":"Reed BN, Sueta CA (2015) A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). Curr Cardiol Rev 11(1):23\u201332","journal-title":"Curr Cardiol Rev"},{"issue":"5","key":"9806_CR4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","volume":"21","author":"CD Kemp","year":"2012","unstructured":"Kemp CD, Conte JV (2012) The pathophysiology of heart failure. Cardiovasc Pathol 21(5):365\u2013371","journal-title":"Cardiovasc Pathol"},{"issue":"2","key":"9806_CR5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2011.05.075","volume":"154","author":"DH MacIver","year":"2012","unstructured":"MacIver DH, Dayer MJ (2012) An alternative approach to understanding the pathophysiological mechanisms of chronic heart failure. Int J Cardiol 154(2):102\u2013110","journal-title":"Int J Cardiol"},{"issue":"7","key":"9806_CR6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J et al (2013) EURObservational research programme: regional differences and 1-year follow-up results of the heart failure pilot survey (ESC-HF pilot). Eur J Heart Fail 15(7):808\u2013817","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"9806_CR7","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"CW Yancy","year":"2016","unstructured":"Yancy CW, Jessup M, Masoudi FA, McBride PE, Peterson PN, Stevenson LW et al (2016) 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure. J Am Coll Cardiol 68(13):1476\u20131488","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"9806_CR8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37(27):2129\u2013U130","journal-title":"Eur Heart J"},{"issue":"5","key":"9806_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.115.002727","volume":"9","author":"M Gheorghiade","year":"2016","unstructured":"Gheorghiade M, Larson CJ, Shah SJ, Greene SJ, Cleland JGF, Colucci WS et al (2016) Developing new treatments for heart failure focus on the heart. Circ Heart Fail 9(5):1\u20138","journal-title":"Circ Heart Fail"},{"issue":"4","key":"9806_CR10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002271","volume":"8","author":"M Vaduganathan","year":"2015","unstructured":"Vaduganathan M, Butler J, Pitt B, Gheorghiade M (2015) Contemporary drug development in heart failure: call for hemodynamically neutral therapies. Circ Heart Fail 8(4):826\u2013831","journal-title":"Circ Heart Fail"},{"issue":"3","key":"9806_CR11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00424-007-0428-7","volume":"457","author":"L Lipskaia","year":"2009","unstructured":"Lipskaia L, Hulot JS, Lompre AM (2009) Role of sarco\/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. Pfl\u00fcgers Archiv: Eur J Physiol 457(3):673\u2013685","journal-title":"Pfl\u00fcgers Archiv: Eur J Physiol"},{"issue":"1","key":"9806_CR12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI62834","volume":"123","author":"AR Marks","year":"2013","unstructured":"Marks AR (2013) Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Investig 123(1):46\u201352","journal-title":"J Clin Investig"},{"issue":"16","key":"9806_CR13","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1073\/pnas.0809777106","volume":"106","author":"AR Lyon","year":"2009","unstructured":"Lyon AR, MacLeod KT, Zhang YJ, Garcia E, Kanda GK, Lab MJ et al (2009) Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. Proc Natl Acad Sci U S A 106(16):6854\u20136859","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"9806_CR14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cardiores.2003.12.031","volume":"62","author":"WE Louch","year":"2004","unstructured":"Louch WE, Bito V, Heinzel FR, Macianskiene R, Vanhaecke J, Flameng W et al (2004) Reduced synchrony of Ca2+ release with loss of T-tubules\u2014a comparison to Ca2+ release in human failing cardiomyocytes. Cardiovasc Res 62(1):63\u201373","journal-title":"Cardiovasc Res"},{"issue":"2","key":"9806_CR15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1113\/jphysiol.2006.107227","volume":"574","author":"WE Louch","year":"2006","unstructured":"Louch WE, Mork HK, Sexton J, Stromme TA, Laake P, Sjaastad I et al (2006) T-tubule disorganization and reduced synchrony of Ca2+ release in murine cardiomyocytes following myocardial infarction. J Physiol 574(2):519\u2013533","journal-title":"J Physiol"},{"issue":"3","key":"9806_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0017901","volume":"6","author":"DJ Crossman","year":"2011","unstructured":"Crossman DJ, Ruygrok PR, Soeller C, Cannell MB (2011) Changes in the organization of excitation-contraction coupling structures in failing human heart. PLoS One 6(3):1\u201310","journal-title":"PLoS One"},{"issue":"8","key":"9806_CR17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cvr\/cvx055","volume":"113","author":"DJ Crossman","year":"2017","unstructured":"Crossman DJ, Shen X, Jullig M, Munro M, Hou Y, Middleditch M et al (2017) Increased collagen within the transverse tubules in human heart failure. Cardiovasc Res 113(8):879\u2013891","journal-title":"Cardiovasc Res"},{"issue":"1","key":"9806_CR18","first-page":"H88","volume":"306","author":"SJ Shah","year":"2014","unstructured":"Shah SJ, Aistrup GL, Gupta DK, O'Toole MJ, Nahhas AF, Schuster D et al (2014) Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. Am J Phys Heart Circ Phys 306(1):H88\u2013H100","journal-title":"Am J Phys Heart Circ Phys"},{"issue":"11","key":"9806_CR19","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1073\/pnas.0509324103","volume":"103","author":"LS Song","year":"2006","unstructured":"Song LS, Sobie EA, McCulle S, Lederer WJ, Balke CW, Cheng HP (2006) Orphaned ryanodine receptors in the failing heart. Proc Natl Acad Sci U S A 103(11):4305\u20134310","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9806_CR20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.yjmcc.2015.04.022","volume":"84","author":"DJ Crossman","year":"2015","unstructured":"Crossman DJ, Young AA, Ruygrok PN, Nason GP, Baddelely D, Soeller C et al (2015) T-tubule disease: relationship between T-tubule organization and regional contractile performance in human dilated cardiomyopathy. J Mol Cell Cardiol 84:170\u2013178","journal-title":"J Mol Cell Cardiol"},{"issue":"42","key":"9806_CR21","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.1411557111","volume":"111","author":"C Crocini","year":"2014","unstructured":"Crocini C, Coppini R, Ferrantini C, Yan P, Loew LM, Tesi C et al (2014) Defects in T-tubular electrical activity underlie local alterations of calcium release in heart failure. Proc Natl Acad Sci U S A 111(42):15196\u201315201","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"9806_CR22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/CIRCRESAHA.109.212324","volume":"107","author":"S Wei","year":"2010","unstructured":"Wei S, Guo A, Chen BY, Kutschke W, Xie YP, Zimmerman K et al (2010) T-tubule remodeling during transition from hypertrophy to heart failure. Circ Res 107(4):520\u2013U163","journal-title":"Circ Res"},{"issue":"1","key":"9806_CR23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvw111","volume":"112","author":"M Frisk","year":"2016","unstructured":"Frisk M, Ruud M, Espe EKS, Aronsen JM, Roe AT, Zhang LL et al (2016) Elevated ventricular wall stress disrupts cardiomyocyte T-tubule structure and calcium homeostasis. Cardiovasc Res 112(1):443\u2013451","journal-title":"Cardiovasc Res"},{"issue":"17","key":"9806_CR24","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.113.008452","volume":"129","author":"CM Zhang","year":"2014","unstructured":"Zhang CM, Chen BY, Guo A, Zhu YQ, Miller JD, Gao S et al (2014) Microtubule-mediated defects in Junctophilin-2 trafficking contribute to myocyte transverse-tubule remodeling and Ca2+ handling dysfunction in heart failure. Circulation. 129(17):1742\u20131750","journal-title":"Circulation."},{"issue":"2","key":"9806_CR25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/cvr\/cvu151","volume":"103","author":"DL Beavers","year":"2014","unstructured":"Beavers DL, Landstrom AP, Chiang DY, Wehrens XHT (2014) Emerging roles of junctophilin-2 in the heart and implications for cardiac diseases. Cardiovasc Res 103(2):198\u2013205","journal-title":"Cardiovasc Res"},{"issue":"9","key":"9806_CR26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/CIRCULATIONAHA.110.006437","volume":"123","author":"RJ van Oort","year":"2011","unstructured":"van Oort RJ, Garbino A, Wang W, Dixit SS, Landstrom AP, Gaur N et al (2011) Disrupted junctional membrane complexes and hyperactive ryanodine receptors after acute junctophilin knockdown in mice. Circulation. 123(9):979\u2013988","journal-title":"Circulation."},{"issue":"12","key":"9806_CR27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/CIRCRESAHA.116.303448","volume":"115","author":"JL Caldwell","year":"2014","unstructured":"Caldwell JL, Smith CER, Taylor RF, Kitmitto A, Eisner DA, Dibb KM et al (2014) Dependence of cardiac transverse tubules on the BAR domain protein amphiphysin II (BIN-1). Circ Res 115(12):986\u2013U157","journal-title":"Circ Res"},{"issue":"6","key":"9806_CR28","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.yjmcc.2007.04.006","volume":"42","author":"AP Landstrom","year":"2007","unstructured":"Landstrom AP, Weisleder N, Batalden KB, Bos JM, Tester DJ, Ommen SR et al (2007) Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol 42(6):1026\u20131035","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"9806_CR29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/CIRCRESAHA.111.257428","volume":"110","author":"FB Sachse","year":"2012","unstructured":"Sachse FB, Torres NS, Savio-Galimberti E, Aiba T, Kass DA, Tomaselli GF et al (2012) Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy. Circ Res 110(4):588\u2013U197","journal-title":"Circ Res"},{"issue":"4","key":"9806_CR30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/aps.2016.13","volume":"37","author":"CK Huang","year":"2016","unstructured":"Huang CK, Chen BY, Guo A, Chen R, Zhu YQ, Kutschke W et al (2016) Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model. Acta Pharmacol Sin 37(4):473\u2013482","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"9806_CR31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1096\/fj.11-199505","volume":"26","author":"B Chen","year":"2012","unstructured":"Chen B, Li Y, Jiang S, Xie YP, Guo A, Kutschke W et al (2012) Beta-adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. FASEB J 26(6):2531\u20132537","journal-title":"FASEB J"},{"key":"9806_CR32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijcard.2016.10.021","volume":"225","author":"JO Reynolds","year":"2016","unstructured":"Reynolds JO, Quick AP, Wang QL, Beavers DL, Philippen LE, Showell J et al (2016) Junctophilin-2 gene therapy rescues heart failure by normalizing RyR2-mediated Ca2+ release. Int J Cardiol 225:371\u2013380","journal-title":"Int J Cardiol"},{"key":"9806_CR33","doi-asserted-by":"crossref","unstructured":"Guo A, Wang Y, Chen B, Wang Y, Yuan J, Zhang L et al (2018) E-C coupling structural protein junctophilin-2 encodes a stress-adaptive transcription regulator. Science 362(6421)","DOI":"10.1126\/science.aan3303"},{"issue":"1","key":"9806_CR34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1172\/JCI114429","volume":"85","author":"JJ Mercadier","year":"1990","unstructured":"Mercadier JJ, Lompr\u00e9 AM, Duc P, Boheler KR, Fraysse JB, Wisnewsky C et al (1990) Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Investig 85(1):305\u2013309","journal-title":"J Clin Investig"},{"issue":"2","key":"9806_CR35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/01.RES.72.2.463","volume":"72","author":"M Arai","year":"1993","unstructured":"Arai M, Alpert NR, Maclennan DH, Barton P, Periasamy M (1993) Alterations in sarcoplasmic-reticulum gene-expression in human heart failure\u2014a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72(2):463\u2013469","journal-title":"Circ Res"},{"issue":"4","key":"9806_CR36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.RES.77.4.759","volume":"77","author":"E Kiss","year":"1995","unstructured":"Kiss E, Ball NA, Kranias EG, Walsh RA (1995) Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca(2+)-ATPase protein levels. Effects on Ca2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res 77(4):759\u2013764","journal-title":"Circ Res"},{"issue":"11","key":"9806_CR37","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1161\/01.CIR.92.11.3220","volume":"92","author":"RHG Schwinger","year":"1995","unstructured":"Schwinger RHG, Bohm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M et al (1995) Unchanged protein levels of SERCA-II and phospholamban but reduced Ca2+ uptake and Ca2+ ATPase activity of cardiac sarcoplasmic-reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 92(11):3220\u20133228","journal-title":"Circulation."},{"issue":"2","key":"9806_CR38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0008-6363(01)00489-8","volume":"53","author":"JB Sande","year":"2002","unstructured":"Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E et al (2002) Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 53(2):382\u2013391","journal-title":"Cardiovasc Res"},{"issue":"7","key":"9806_CR39","doi-asserted-by":"crossref","first-page":"H1018","DOI":"10.1152\/ajpheart.00741.2013","volume":"306","author":"NT Boardman","year":"2014","unstructured":"Boardman NT, Aronsen JM, Louch WE, Sjaastad I, Willoch F, Christensen G et al (2014) Impaired left ventricular mechanical and energetic function in mice after cardiomyocyte-specific excision of SERCA2. Am J Physiol-Heart Circ Physiol 306(7):H1018\u2013H1024","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"8","key":"9806_CR40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm739","volume":"8","author":"M Hoshijima","year":"2002","unstructured":"Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y et al (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8(8):864\u2013871","journal-title":"Nat Med"},{"issue":"8","key":"9806_CR41","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/hc0802.105564","volume":"105","author":"F del Monte","year":"2002","unstructured":"del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ (2002) Targeting phospholamban by gene transfer in human heart failure. Circulation. 105(8):904","journal-title":"Circulation."},{"issue":"3","key":"9806_CR42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jacc.2007.03.047","volume":"50","author":"DM Kaye","year":"2007","unstructured":"Kaye DM, Preovolos A, Marshall T, Byrne M, Hoshijima M, Hajjar R et al (2007) Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 50(3):253","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"9806_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0168486","volume":"11","author":"M Kaneko","year":"2016","unstructured":"Kaneko M, Hashikami K, Yamamoto S, Matsumoto H, Nishimoto T (2016) Phospholamban ablation using CRISPR\/Cas9 system improves mortality in a murine heart failure model. PLoS One 11(12):1\u201316","journal-title":"PLoS One"},{"issue":"8","key":"9806_CR44","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1096\/fj.05-5299fje","volume":"20","author":"M Yamada","year":"2006","unstructured":"Yamada M, Ikeda Y, Yano M, Yoshimura K, Nishino S, Aoyama H et al (2006) Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J 20(8):1197\u20131199","journal-title":"FASEB J"},{"issue":"6","key":"9806_CR45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1172\/JCI17892","volume":"111","author":"K Haghighi","year":"2003","unstructured":"Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO et al (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Investig 111(6):869\u2013876","journal-title":"J Clin Investig"},{"issue":"11","key":"9806_CR46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","volume":"14","author":"PA van der Zwaag","year":"2012","unstructured":"van der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiesfeld AC et al (2012) Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 14(11):1199\u20131207","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"9806_CR47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCRESAHA.116.310007","volume":"120","author":"EG Kranias","year":"2017","unstructured":"Kranias EG, Hajjar RJ (2017) The phospholamban journey 4 decades after setting out for Ithaka. Circ Res 120(5):781\u2013783","journal-title":"Circ Res"},{"issue":"3","key":"9806_CR48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/bph.12288","volume":"170","author":"CLH Huang","year":"2013","unstructured":"Huang CLH (2013) SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications. Br J Pharmacol 170(3):486\u2013488","journal-title":"Br J Pharmacol"},{"issue":"2A","key":"9806_CR49","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/j.amjcard.2006.09.003","volume":"99","author":"R Micheletti","year":"2007","unstructured":"Micheletti R, Palazzo F, Barassi P, Glacalone G, Ferrandi M, Schiavone A et al (2007) Istaroxime, a stimulator of sarcoplasmic, reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol 99(2A):24A\u201332A","journal-title":"Am J Cardiol"},{"issue":"2A","key":"9806_CR50","doi-asserted-by":"crossref","first-page":"41A","DOI":"10.1016\/j.amjcard.2006.09.005","volume":"99","author":"HN Sabbah","year":"2007","unstructured":"Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M (2007) Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol 99(2A):41A\u201346A","journal-title":"Am J Cardiol"},{"issue":"4","key":"9806_CR51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4103\/0976-500X.103705","volume":"3","author":"S Aditya","year":"2012","unstructured":"Aditya S, Rattan A (2012) Istaroxime: a rising star in acute heart failure. J Pharmacol Pharmacother 3(4):353\u2013355","journal-title":"J Pharmacol Pharmacother"},{"issue":"15","key":"9806_CR52","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1161\/01.CIR.0000124230.60028.42","volume":"109","author":"Y Chen","year":"2004","unstructured":"Chen Y, Escoubet B, Prunier F, Amour J, Simonides WS, Vivien B et al (2004) Constitutive cardiac overexpression of sarcoplasmic\/endoplasmic reticulum Ca2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation. 109(15):1898\u20131903","journal-title":"Circulation."},{"issue":"23","key":"9806_CR53","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1161\/01.CIR.100.23.2308","volume":"100","author":"M Federica del","year":"1999","unstructured":"Federica del M, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW et al (1999) Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 100(23):2308","journal-title":"Circulation."},{"issue":"2","key":"9806_CR54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.97.2.793","volume":"97","author":"MI Miyamoto","year":"2000","unstructured":"Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T et al (2000) Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 97(2):793\u2013798","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"9806_CR55","first-page":"H1204","volume":"292","author":"S Sakata","year":"2007","unstructured":"Sakata S, Lebeche D, Sakata Y, Sakata N, Chemaly ER, Liang LF et al (2007) Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Phys Heart Circ Phys 292(2):H1204\u2013H12H7","journal-title":"Am J Phys Heart Circ Phys"},{"issue":"3","key":"9806_CR56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/CIRCEP.110.961615","volume":"4","author":"AR Lyon","year":"2011","unstructured":"Lyon AR, Bannister ML, Collins T, Pearce E, Sepehripour AH, Dubb SS et al (2011) SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol 4(3):362\u2013372","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"12","key":"9806_CR57","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/hc3601.095574","volume":"104","author":"F del Monte","year":"2001","unstructured":"del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK et al (2001) Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation. 104(12):1424\u20131429","journal-title":"Circulation."},{"issue":"6","key":"9806_CR58","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/gt.2012.3","volume":"19","author":"K Ishikawa","year":"2012","unstructured":"Ishikawa K, Tilemann L, Ladage D, Aguero J, Leonardson L, Fish K et al (2012) Cardiac gene therapy in large animals: bridge from bench to bedside. Gene Ther 19(6):670\u2013677","journal-title":"Gene Ther"},{"issue":"4","key":"9806_CR59","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.yjmcc.2007.01.003","volume":"42","author":"S Sakata","year":"2007","unstructured":"Sakata S, Lebeche D, Sakata N, Sakata Y, Chemaly ER, Liang LF et al (2007) Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 42(4):852\u2013861","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"9806_CR60","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/eurheartj\/ehs043","volume":"33","author":"R Kumarswamy","year":"2012","unstructured":"Kumarswamy R, Lyon AR, Volkmann I, Mills AM, Bretthauer J, Pahuja A et al (2012) SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt\/FoxO3A-dependent pathway. Eur Heart J 33(9):1067\u20131075","journal-title":"Eur Heart J"},{"issue":"11","key":"9806_CR61","doi-asserted-by":"crossref","first-page":"E66-E","DOI":"10.1161\/hh1101.092004","volume":"88","author":"F del Monte","year":"2001","unstructured":"del Monte F, Hajjar RJ, Harding SE (2001) Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circulation Research 88(11):E66-E","journal-title":"Circulation Research"},{"issue":"3","key":"9806_CR62","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"M Jessup","year":"2011","unstructured":"Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al (2011) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 124(3):304\u2013313","journal-title":"Circulation."},{"issue":"1","key":"9806_CR63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","volume":"114","author":"K Zsebo","year":"2014","unstructured":"Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M et al (2014) Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114(1):101\u2013108","journal-title":"Circ Res"},{"issue":"10024","key":"9806_CR64","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","volume":"387","author":"B Greenberg","year":"2016","unstructured":"Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS et al (2016) Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 387(10024):1178\u20131186","journal-title":"Lancet."},{"key":"9806_CR65","doi-asserted-by":"crossref","unstructured":"Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P et al (2017) Effect of intracoronary administration of AAV1\/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial. Eur J Heart Fail 19(11):1534\u20131541","DOI":"10.1002\/ejhf.826"},{"issue":"5","key":"9806_CR66","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/hum.2016.166","volume":"28","author":"WF Penny","year":"2017","unstructured":"Penny WF, Hammond HK (2017) Randomized clinical trials of gene transfer for heart failure with reduced ejection fraction. Hum Gene Ther 28(5):378\u2013384","journal-title":"Hum Gene Ther"},{"issue":"10","key":"9806_CR67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1139\/cjpp-2014-0463","volume":"93","author":"AN Stammers","year":"2015","unstructured":"Stammers AN, Susser SE, Hamm NC, Hlynsky MW, Kimber DE, Kehler DS et al (2015) The regulation of sarco(endo)plasmic reticulum calcium-ATPases (SERCA). Can J Physiol Pharmacol 93(10):843\u2013854","journal-title":"Can J Physiol Pharmacol"},{"issue":"45","key":"9806_CR68","doi-asserted-by":"crossref","first-page":"44230","DOI":"10.1074\/jbc.M303810200","volume":"278","author":"RJ Clark","year":"2003","unstructured":"Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M et al (2003) Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278(45):44230\u201344237","journal-title":"J Biol Chem"},{"issue":"4","key":"9806_CR69","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.hlc.2015.11.008","volume":"25","author":"A Lee","year":"2016","unstructured":"Lee A, Oh JG, Gorski PA, Hajjar RJ, Kho C (2016) Post-translational modifications in heart failure: small changes, big impact. Heart Lung Circ 25(4):319\u2013324","journal-title":"Heart Lung Circ"},{"issue":"1","key":"9806_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2005.03.012","volume":"18","author":"RT Hay","year":"2005","unstructured":"Hay RT (2005) SUMO: a history of modification. Mol Cell 18(1):1\u201312","journal-title":"Mol Cell"},{"issue":"7366","key":"9806_CR71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nature10407","volume":"477","author":"C Kho","year":"2011","unstructured":"Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, Kizana E et al (2011) SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 477(7366):601\u2013605","journal-title":"Nature."},{"issue":"211","key":"9806_CR72","doi-asserted-by":"crossref","first-page":"211ra159","DOI":"10.1126\/scitranslmed.3006487","volume":"5","author":"L Tilemann","year":"2013","unstructured":"Tilemann L, Lee A, Ishikawa K, Aguero J, Rapti K, Santos-Gallego C et al (2013) SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med 5(211):211ra159","journal-title":"Sci Transl Med"},{"key":"9806_CR73","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1038\/ncomms8229","volume":"6","author":"C Kho","year":"2015","unstructured":"Kho C, Lee A, Jeong D, Oh JG, Gorski PA, Fish K et al (2015) Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. Nat Commun 6:7229","journal-title":"Nat Commun"},{"key":"9806_CR74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.physiol.70.113006.100455","volume":"70","author":"DM Bers","year":"2008","unstructured":"Bers DM (2008) Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70:23\u201349","journal-title":"Annu Rev Physiol"},{"key":"9806_CR75","volume-title":"An account of the foxglove, and some of its medical uses: with practical remarks on dropsy, and other diseases","author":"W Withering","year":"1785","unstructured":"Withering W (1785) An account of the foxglove, and some of its medical uses: with practical remarks on dropsy, and other diseases. Birmingham, England"},{"issue":"2","key":"9806_CR76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0735-1097(84)80231-4","volume":"4","author":"H Scholz","year":"1984","unstructured":"Scholz H (1984) Inotropic drugs and their mechanisms of action. J Am Coll Cardiol 4(2):389\u2013397","journal-title":"J Am Coll Cardiol"},{"key":"9806_CR77","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2015.10.240","volume":"203","author":"P Pollesello","year":"2016","unstructured":"Pollesello P, Papp Z, Papp JG (2016) Calcium sensitizers: what have we learned over the last 25 years? Int J Cardiol 203:543\u2013548","journal-title":"Int J Cardiol"},{"issue":"1","key":"9806_CR78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0735-1097(94)00353-R","volume":"25","author":"M Bohm","year":"1995","unstructured":"Bohm M, La Rosee K, Schwinger RH, Erdmann E (1995) Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25(1):146\u2013153","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9806_CR79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-9343(80)90387-3","volume":"69","author":"DA Unverferth","year":"1980","unstructured":"Unverferth DA, Blanford M, Kates RE, Leier CV (1980) Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med 69(2):262\u2013266","journal-title":"Am J Med"},{"issue":"4","key":"9806_CR80","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJM198207223070401","volume":"307","author":"MR Bristow","year":"1982","unstructured":"Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307(4):205\u2013211","journal-title":"N Engl J Med"},{"issue":"6","key":"9806_CR81","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/01.CIR.70.6.1038","volume":"70","author":"M Packer","year":"1984","unstructured":"Packer M, Medina N, Yushak M (1984) Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation. 70(6):1038","journal-title":"Circulation."},{"issue":"21","key":"9806_CR82","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"M Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325(21):1468\u20131475","journal-title":"N Engl J Med"},{"issue":"4","key":"9806_CR83","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0002-8703(86)90475-8","volume":"112","author":"MJ Krell","year":"1986","unstructured":"Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N et al (1986) Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 112(4):787\u2013791","journal-title":"Am Heart J"},{"issue":"20","key":"9806_CR84","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2014.01.016","volume":"63","author":"GS Francis","year":"2014","unstructured":"Francis GS, Bartos JA, Adatya S (2014) Inotropes. J Am Coll Cardiol 63(20):2069\u20132078","journal-title":"J Am Coll Cardiol"},{"issue":"4 Suppl A","key":"9806_CR85","doi-asserted-by":"crossref","first-page":"119A","DOI":"10.1016\/0735-1097(93)90474-F","volume":"22","author":"M Packer","year":"1993","unstructured":"Packer M (1993) The development of positive inotropic agents for chronic heart failure: how have we gone astray. J Am Coll Cardiol 22(4 Suppl A):119A\u2013126A","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"9806_CR86","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"G Perry","year":"1997","unstructured":"Perry G, Brown E, Thornton R, Shiva T, Hubbard J, Reddy KR et al (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525\u2013533","journal-title":"N Engl J Med"},{"issue":"6","key":"9806_CR87","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","volume":"41","author":"GM Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41(6):997\u20131003","journal-title":"J Am Coll Cardiol"},{"issue":"1 Pt 1","key":"9806_CR88","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","volume":"138","author":"CM O'Connor","year":"1999","unstructured":"O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH et al (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138(1 Pt 1):78\u201386","journal-title":"Am Heart J"},{"issue":"3","key":"9806_CR89","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","volume":"38","author":"CL Tacon","year":"2012","unstructured":"Tacon CL, McCaffrey J, Delaney A (2012) Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 38(3):359\u2013367","journal-title":"Intensive Care Med"},{"issue":"9","key":"9806_CR90","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00134-016-4449-6","volume":"42","author":"G Koster","year":"2016","unstructured":"Koster G, Bekema HJ, Wetterslev J, Gluud C, Keus F, van der Horst ICC (2016) Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med 42(9):1322\u20131335","journal-title":"Intensive Care Med"},{"key":"9806_CR91","first-page":"1","volume":"351","author":"OJ Ziff","year":"2015","unstructured":"Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH et al (2015) Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. Br Med J 351:1\u20139","journal-title":"Br Med J"},{"issue":"2","key":"9806_CR92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","volume":"149","author":"KF Adams Jr","year":"2005","unstructured":"Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209\u2013216","journal-title":"Am Heart J"},{"issue":"Suppl","key":"9806_CR93","first-page":"103","volume":"12","author":"Y Goto","year":"1997","unstructured":"Goto Y, Hata K (1997) Mechanoenergetic effect of pimobendan in failing dog hearts. Heart Vessel 12(Suppl):103\u2013105","journal-title":"Heart Vessel"},{"issue":"2","key":"9806_CR94","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00005344-199402000-00014","volume":"23","author":"H Asanoi","year":"1994","unstructured":"Asanoi H, Ishizaka S, Kameyama T, Ishise H, Sasayama S (1994) Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 23(2):268\u2013274","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"9806_CR95","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cvsm.2010.04.003","volume":"40","author":"A Boswood","year":"2010","unstructured":"Boswood A (2010) Current use of pimobendan in canine patients with heart disease. Vet Clin N Am Small Anim Pract 40(4):571\u2013580","journal-title":"Vet Clin N Am Small Anim Pract"},{"issue":"3","key":"9806_CR96","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/hrt.76.3.223","volume":"76","author":"J Lubsen","year":"1996","unstructured":"Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J et al (1996) Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 76(3):223\u2013231","journal-title":"Heart."},{"issue":"2","key":"9806_CR97","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1253\/circj.66.149","volume":"66","author":"K Kato","year":"2002","unstructured":"Kato K, Iizuka M, Yazaki Y, Sasayama S, Nakashima M, Ohashi Y et al (2002) Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure\u2014the effects of pimobendan on chronic heart failure study (EPOCH study). Circulation 66(2):149\u2013157","journal-title":"Circulation"},{"issue":"2","key":"9806_CR98","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenpera M, Leppikangas H et al (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 159(2):82\u201387","journal-title":"Int J Cardiol"},{"issue":"43","key":"9806_CR99","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1021\/acs.biochem.6b00758","volume":"55","author":"IM Robertson","year":"2016","unstructured":"Robertson IM, Pineda-Sanabria SE, Yan Z, Kampourakis T, Sun YB, Sykes BD et al (2016) Reversible covalent binding to cardiac troponin C by the Ca2+-sensitizer Levosimendan. Biochemistry. 55(43):6032\u20136045","journal-title":"Biochemistry."},{"issue":"2","key":"9806_CR100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbadis.2005.06.003","volume":"1762","author":"HTF Facundo","year":"2006","unstructured":"Facundo HTF, Fornazari M, Kowaltowski AJ (2006) Tissue protection mediated by mitochondrial K+ channels. Biochim Biophys Acta (BBA)-Mol Basis Dis 1762(2):202\u2013212","journal-title":"Biochim Biophys Acta (BBA)-Mol Basis Dis"},{"issue":"4","key":"9806_CR101","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00005344-200404000-00011","volume":"43","author":"P Kaheinen","year":"2004","unstructured":"Kaheinen P, Pollesello P, Levijoki J, Haikala H (2004) Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 43(4):555\u2013561","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"9806_CR102","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0009-9236(97)90139-9","volume":"61","author":"H Ukkonen","year":"1997","unstructured":"Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K et al (1997) Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 61(5):596\u2013607","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"9806_CR103","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2015-308137","volume":"102","author":"M Tarkia","year":"2016","unstructured":"Tarkia M, Stark C, Haavisto M, Kentala R, V\u00e4h\u00e4silta T, Savunen T et al (2016) Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion. Heart. 102(6):465","journal-title":"Heart."},{"issue":"2","key":"9806_CR104","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00395-009-0064-9","volume":"105","author":"A Honisch","year":"2010","unstructured":"Honisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C (2010) Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol 105(2):155\u2013167","journal-title":"Basic Res Cardiol"},{"key":"9806_CR105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijcard.2016.05.009","volume":"218","author":"MS Nieminen","year":"2016","unstructured":"Nieminen MS, Buerke M, Cohen-Solal A, Costa S, Edes I, Erlikh A et al (2016) The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol 218:150\u2013157","journal-title":"Int J Cardiol"},{"issue":"9328","key":"9806_CR106","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 360(9328):196\u2013202","journal-title":"Lancet."},{"issue":"18","key":"9806_CR107","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","volume":"23","author":"VS Moiseyev","year":"2002","unstructured":"Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB et al (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23(18):1422\u20131432","journal-title":"Eur Heart J"},{"issue":"17","key":"9806_CR108","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. J Am Med Assoc 297(17):1883\u20131891","journal-title":"J Am Med Assoc"},{"issue":"2","key":"9806_CR109","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/CCM.0b013e318232962a","volume":"40","author":"G Landoni","year":"2012","unstructured":"Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A et al (2012) Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 40(2):634\u2013646","journal-title":"Crit Care Med"},{"issue":"11","key":"9806_CR110","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.282.11.1054","volume":"282","author":"P J\u00fcni","year":"1999","unstructured":"J\u00fcni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. J Am Med Assoc 282(11):1054\u20131060","journal-title":"J Am Med Assoc"},{"issue":"4","key":"9806_CR111","first-page":"227","volume":"5","author":"MS Nieminen","year":"2013","unstructured":"Nieminen MS, Fruhwald S, Heunks LMA, Suominen PK, Gordon AC, Kivikko M et al (2013) Levosimendan: current data, clinical use and future development. Heart Lung Vessels 5(4):227\u2013245","journal-title":"Heart Lung Vessels"},{"issue":"8","key":"9806_CR112","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","volume":"16","author":"J Altenberger","year":"2014","unstructured":"Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A et al (2014) Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail 16(8):898\u2013906","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"9806_CR113","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijcard.2014.04.111","volume":"174","author":"MS Nieminen","year":"2014","unstructured":"Nieminen MS, Altenberger J, Ben-Gal T, Bohmer A, Comin-Colet J, Dickstein K et al (2014) Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol 174(2):360\u2013367","journal-title":"Int J Cardiol"},{"issue":"23","key":"9806_CR114","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1111\/bph.12647","volume":"171","author":"O Orstavik","year":"2014","unstructured":"Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, Levy FO et al (2014) Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol 171(23):5169\u20135181","journal-title":"Br J Pharmacol"},{"issue":"20","key":"9806_CR115","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1161\/01.CIR.98.20.2141","volume":"98","author":"G Hasenfuss","year":"1998","unstructured":"Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H (1998) Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 98(20):2141\u20132147","journal-title":"Circulation."},{"key":"9806_CR116","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","volume":"222","author":"D Farmakis","year":"2016","unstructured":"Farmakis D, Alvarez J, Ben Gal T, Brito D, Fedele F, Fonseca C et al (2016) Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol 222:303\u2013312","journal-title":"Int J Cardiol"},{"issue":"4","key":"9806_CR117","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10741-009-9135-0","volume":"14","author":"JR Teerlink","year":"2009","unstructured":"Teerlink JR (2009) A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 14(4):289\u2013298","journal-title":"Heart Fail Rev"},{"issue":"5","key":"9806_CR118","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrd4554","volume":"14","author":"PM Hwang","year":"2015","unstructured":"Hwang PM, Sykes BD (2015) Targeting the sarcomere to correct muscle function. Nat Rev Drug Discov 14(5):313\u2013328","journal-title":"Nat Rev Drug Discov"},{"key":"9806_CR119","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.yjmcc.2015.06.011","volume":"85","author":"R Mamidi","year":"2015","unstructured":"Mamidi R, Gresham KS, Li A, dos Remedios CG, Stelzer JE (2015) Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. J Mol Cell Cardiol 85:262\u2013272","journal-title":"J Mol Cell Cardiol"},{"issue":"9792","key":"9806_CR120","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","volume":"378","author":"JR Teerlink","year":"2011","unstructured":"Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD et al (2011) Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 378(9792):667\u2013675","journal-title":"Lancet."},{"issue":"9792","key":"9806_CR121","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","volume":"378","author":"JGF Cleland","year":"2011","unstructured":"Cleland JGF, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJV, Lang CC et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 378(9792):676\u2013683","journal-title":"Lancet."},{"issue":"12","key":"9806_CR122","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","volume":"67","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS et al (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure the ATOMIC-AHF study. J Am Coll Cardiol 67(12):1444\u20131455","journal-title":"J Am Coll Cardiol"},{"issue":"10062","key":"9806_CR123","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV, Solomon SD, Adams KF, Cleland JGF et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 388(10062):2895\u20132903","journal-title":"Lancet."},{"issue":"1","key":"9806_CR124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchf.2014.07.009","volume":"3","author":"BH Greenberg","year":"2015","unstructured":"Greenberg BH, Chou W, Saikali KG, Escand\u00f3n R, Lee JH, Chen MM et al (2015) Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail 3(1):22\u201329","journal-title":"JACC Heart Fail"},{"issue":"18","key":"9806_CR125","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1111\/bph.13235","volume":"172","author":"L Nagy","year":"2015","unstructured":"Nagy L, Kovacs A, Bodi B, Pasztor ET, Fulop GA, Toth A et al (2015) The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat. Br J Pharmacol 172(18):4506\u20134518","journal-title":"Br J Pharmacol"},{"issue":"4","key":"9806_CR126","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/CIRCHEARTFAILURE.114.002152","volume":"8","author":"JP Bakkehaug","year":"2015","unstructured":"Bakkehaug JP, Kildal AB, Engstad ET, Boardman N, Naesheim T, Ronning L et al (2015) Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity. Circ-Heart Fail 8(4):766\u2013775","journal-title":"Circ-Heart Fail"},{"issue":"2 Pt 1","key":"9806_CR127","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0002-8703(99)70108-0","volume":"138","author":"F Oliva","year":"1999","unstructured":"Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E et al (1999) Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 138(2 Pt 1):247\u2013253","journal-title":"Am Heart J"},{"issue":"25","key":"9806_CR128","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJM199812173392503","volume":"339","author":"JN Cohn","year":"1998","unstructured":"Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE et al (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 339(25):1810\u20131816","journal-title":"N Engl J Med"},{"issue":"12","key":"9806_CR129","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","volume":"287","author":"MS Cuffe","year":"2002","unstructured":"Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 287(12):1541\u20131547","journal-title":"JAMA."},{"issue":"16","key":"9806_CR130","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/eurheartj\/ehi875","volume":"27","author":"L De Luca","year":"2006","unstructured":"De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M (2006) Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27(16):1908\u20131920","journal-title":"Eur Heart J"},{"key":"9806_CR131","first-page":"3363","volume":"112","author":"M Packer","year":"2005","unstructured":"Packer M (2005) Revive II trial investigators: REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation. 112:3363","journal-title":"Circulation."},{"issue":"23","key":"9806_CR132","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.jacc.2008.03.015","volume":"51","author":"M Gheorghiade","year":"2008","unstructured":"Gheorghiade M, Blair JEA, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J et al (2008) Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent\u2014a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 51(23):2276\u20132285","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"9806_CR133","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","volume":"113","author":"T Doenst","year":"2013","unstructured":"Doenst T, Nguyen TD, Abel ED (2013) Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res 113(6):709\u2013724","journal-title":"Circ Res"},{"issue":"4","key":"9806_CR134","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","volume":"14","author":"DA Brown","year":"2017","unstructured":"Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR et al (2017) Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol 14(4):238\u2013250","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"9806_CR135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/01.CIR.99.4.578","volume":"99","author":"C Depre","year":"1999","unstructured":"Depre C, Vanoverschelde J-LJ, Taegtmeyer H (1999) Glucose for the heart. Circulation. 99(4):578\u2013588","journal-title":"Circulation."},{"issue":"17","key":"9806_CR136","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJM198510243131704","volume":"313","author":"JS Ingwall","year":"1985","unstructured":"Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W et al (1985) The creatine kinase system in normal and diseased human myocardium. N Engl J Med 313(17):1050\u20131054","journal-title":"N Engl J Med"},{"issue":"9","key":"9806_CR137","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2003.05.005","volume":"42","author":"I Nakae","year":"2003","unstructured":"Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo S et al (2003) Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 42(9):1587\u20131593","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"9806_CR138","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1073\/pnas.0408962102","volume":"102","author":"RG Weiss","year":"2005","unstructured":"Weiss RG, Gerstenblith G, Bottomley PA (2005) ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci U S A 102(3):808\u2013813","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"9806_CR139","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1161\/01.CIR.96.7.2190","volume":"96","author":"S Neubauer","year":"1997","unstructured":"Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W et al (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 96(7):2190\u20132196","journal-title":"Circulation."},{"issue":"7","key":"9806_CR140","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.bbamcr.2011.01.015","volume":"1813","author":"JS Jaswal","year":"2011","unstructured":"Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD (2011) Targeting fatty acid and carbohydrate oxidation\u2014a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813(7):1333\u20131350","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"9806_CR141","first-page":"49","volume":"8","author":"J Karbowska","year":"2003","unstructured":"Karbowska J, Kochan Z, Smolenski RT (2003) Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart. Cell Mol Biol Lett 8(1):49\u201353","journal-title":"Cell Mol Biol Lett"},{"issue":"2","key":"9806_CR142","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.yjmcc.2008.10.025","volume":"46","author":"S Sihag","year":"2009","unstructured":"Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ (2009) PGC-1 alpha and ERR alpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46(2):201\u2013212","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"9806_CR143","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/cvr\/cvr071","volume":"90","author":"SC Kolwicz","year":"2011","unstructured":"Kolwicz SC, Tian R (2011) Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 90(2):194\u2013201","journal-title":"Cardiovasc Res"},{"issue":"15","key":"9806_CR144","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/CIRCULATIONAHA.106.668665","volume":"115","author":"N Sorokina","year":"2007","unstructured":"Sorokina N, O\u2019Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF et al (2007) Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation. 115(15):2033\u20132041","journal-title":"Circulation."},{"key":"9806_CR145","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijcard.2015.11.060","volume":"203","author":"YM Lopatin","year":"2016","unstructured":"Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH et al (2016) Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol 203:909\u2013915","journal-title":"Int J Cardiol"},{"issue":"4","key":"9806_CR146","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/hrt.2010.208751","volume":"97","author":"D Gao","year":"2011","unstructured":"Gao D, Ning N, Niu X, Hao G, Meng Z (2011) Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 97(4):278\u2013286","journal-title":"Heart."},{"issue":"3","key":"9806_CR147","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijcard.2012.09.123","volume":"163","author":"G Fragasso","year":"2013","unstructured":"Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L et al (2013) Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol 163(3):320\u2013325","journal-title":"Int J Cardiol"},{"issue":"21","key":"9806_CR148","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1161\/CIRCULATIONAHA.105.551457","volume":"112","author":"L Lee","year":"2005","unstructured":"Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L et al (2005) Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 112(21):3280\u20133288","journal-title":"Circulation."},{"issue":"3","key":"9806_CR149","first-page":"202","volume":"3","author":"RM Beadle","year":"2015","unstructured":"Beadle RM, Williams LK, Kuehl M, Bowater S, Abozguia K, Leyva F et al (2015) Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. J American C C: Heart Fail 3(3):202\u2013211","journal-title":"J American C C: Heart Fail"},{"issue":"6","key":"9806_CR150","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/01.fjc.0000190488.77434.f1","volume":"46","author":"SA Unger","year":"2005","unstructured":"Unger SA, Kennedy JA, McFadden-Lewis K, Minerds K, Murphy GA, Horowitz JD (2005) Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium. J Cardiovasc Pharmacol 46(6):849\u2013855","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"9806_CR151","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10557-016-6664-3","volume":"30","author":"CR Chong","year":"2016","unstructured":"Chong CR, Sallustio B, Horowitz JD (2016) Drugs that affect cardiac metabolism: focus on Perhexiline. Cardiovasc Drugs Ther 30(4):399\u2013405","journal-title":"Cardiovasc Drugs Ther"},{"key":"9806_CR152","doi-asserted-by":"crossref","unstructured":"Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA et al (2003) Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 13(10):627\u2013632","DOI":"10.1097\/00008571-200310000-00006"},{"key":"9806_CR153","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijcard.2016.10.102","volume":"227","author":"K Banerjee","year":"2017","unstructured":"Banerjee K, Ghosh RK, Kamatam S, Banerjee A, Gupta A (2017) Role of Ranolazine in cardiovascular disease and diabetes: exploring beyond angina. Int J Cardiol 227:556\u2013564","journal-title":"Int J Cardiol"},{"issue":"suppl 4","key":"9806_CR154","first-page":"iv6","volume":"92","author":"L Belardinelli","year":"2006","unstructured":"Belardinelli L, Shryock JC, Fraser H (2006) Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 92(suppl 4):iv6","journal-title":"Heart."},{"issue":"7","key":"9806_CR155","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/0735-1097(94)90665-3","volume":"23","author":"RM Bersin","year":"1994","unstructured":"Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K et al (1994) Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23(7):1617\u20131624","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"9806_CR156","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/clc.4960211206","volume":"21","author":"JF Lewis","year":"1998","unstructured":"Lewis JF, DaCosta M, Wargowich T, Stacpoole P (1998) Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol 21(12):888\u2013892","journal-title":"Clin Cardiol"},{"issue":"7","key":"9806_CR157","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cjca.2016.12.013","volume":"33","author":"GD Lopaschuk","year":"2016","unstructured":"Lopaschuk GD (2016) Metabolic modulators in heart disease: past, present, and future. Can J Cardiol 33(7):838\u2013849","journal-title":"Can J Cardiol"},{"issue":"20","key":"9806_CR158","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1161\/CIRCULATIONAHA.106.645184","volume":"114","author":"H Tuunanen","year":"2006","unstructured":"Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE et al (2006) Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 114(20):2130\u20132137","journal-title":"Circulation."},{"issue":"11","key":"9806_CR159","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","volume":"118","author":"PC Schulze","year":"2016","unstructured":"Schulze PC, Drosatos K, Goldberg IJ (2016) Lipid use and misuse by the heart. Circ Res 118(11):1736\u20131751","journal-title":"Circ Res"},{"issue":"1","key":"9806_CR160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","volume":"109","author":"BN Finck","year":"2002","unstructured":"Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A et al (2002) The cardiac phenotype induced by PPAR-alpha overexpression mimics that caused by diabetes mellitus. J Clin Investig 109(1):121\u2013130","journal-title":"J Clin Investig"},{"issue":"2","key":"9806_CR161","first-page":"H305","volume":"312","author":"S Kaimoto","year":"2017","unstructured":"Kaimoto S, Hoshino A, Ariyoshi M, Okawa Y, Tateishi S, Ono K et al (2017) Activation of PPAR-alpha in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure. Am J Phys Heart Circ Phys 312(2):H305\u2013HH13","journal-title":"Am J Phys Heart Circ Phys"},{"key":"9806_CR162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/835985","volume":"2015","author":"CJ Pol","year":"2015","unstructured":"Pol CJ, Lieu M, Drosatos K (2015) PPARs: protectors or opponents of myocardial function? PPAR Res 2015:1\u201319","journal-title":"PPAR Res"},{"issue":"20","key":"9806_CR163","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al (1987) Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317(20):1237\u20131245","journal-title":"N Engl J Med"},{"issue":"1","key":"9806_CR164","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-010-9208-0","volume":"17","author":"S Sarma","year":"2012","unstructured":"Sarma S, Ardehali H, Gheorghiade M (2012) Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Fail Rev 17(1):35\u201343","journal-title":"Heart Fail Rev"},{"issue":"1","key":"9806_CR165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90(1):207\u2013258","journal-title":"Physiol Rev"},{"issue":"4","key":"9806_CR166","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.hfc.2014.07.006","volume":"10","author":"JG Cleland","year":"2014","unstructured":"Cleland JG, Hutchinson K, Pellicori P, Clark A (2014) Lipid-modifying treatments for heart failure: is their use justified? Heart Fail Clin 10(4):621\u2013634","journal-title":"Heart Fail Clin"},{"key":"9806_CR167","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.yjmcc.2012.09.002","volume":"55","author":"MG Rosca","year":"2013","unstructured":"Rosca MG, Tandler B, Hoppel CL (2013) Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 55:31\u201341","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"9806_CR168","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2013.12.014","volume":"171","author":"K Schwarz","year":"2014","unstructured":"Schwarz K, Siddiqi N, Singh S, Neil CJ, Dawson DK, Frenneaux MP (2014) The breathing heart\u2014mitochondrial respiratory chain dysfunction in cardiac disease. Int J Cardiol 171(2):134\u2013143","journal-title":"Int J Cardiol"},{"issue":"11","key":"9806_CR169","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.cjca.2015.08.017","volume":"31","author":"C Brunel-Guitton","year":"2015","unstructured":"Brunel-Guitton C, Levtova A, Sasarman F (2015) Mitochondrial diseases and cardiomyopathies. Can J Cardiol 31(11):1360\u20131376","journal-title":"Can J Cardiol"},{"key":"9806_CR170","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6353469","volume":"2016","author":"A Arcaro","year":"2016","unstructured":"Arcaro A, Pirozzi F, Angelini A, Chimenti C, Crotti L, Giordano C et al (2016) Novel perspectives in redox biology and pathophysiology of failing myocytes: modulation of the intramyocardial redox milieu for therapeutic interventions\u2014a review article from the working group of cardiac cell biology, Italian Society of Cardiology. Oxidative Med Cell Longev 2016:6353469","journal-title":"Oxidative Med Cell Longev"},{"issue":"1","key":"9806_CR171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0169743","volume":"12","author":"L Grois","year":"2017","unstructured":"Grois L, Hupf J, Reinders J, Schroder J, Dietl A, Schmid PM et al (2017) Combined inhibition of the renin-angiotensin system and neprilysin positively influences complex mitochondrial adaptations in progressive experimental heart failure. PLoS One 12(1):1\u201321","journal-title":"PLoS One"},{"issue":"4","key":"9806_CR172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.115.002639","volume":"9","author":"A Sharma","year":"2016","unstructured":"Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM (2016) Coenzyme Q10 and heart failure: a state-of-the-art review. Circ-Heart Fail 9(4):1\u20138","journal-title":"Circ-Heart Fail"},{"issue":"18","key":"9806_CR173","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2008.07.044","volume":"52","author":"SL Molyneux","year":"2008","unstructured":"Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M et al (2008) Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 52(18):1435\u20131441","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9806_CR174","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10741-016-9588-x","volume":"22","author":"P Parihar","year":"2017","unstructured":"Parihar P, Parihar MS (2017) Metabolic enzymes dysregulation in heart failure: the prospective therapy. Heart Fail Rev 22(1):109\u2013121","journal-title":"Heart Fail Rev"},{"issue":"4","key":"9806_CR175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-079X.2010.00759.x","volume":"48","author":"G Paradies","year":"2010","unstructured":"Paradies G, Petrosillo G, Paradies V, Reiter RJ, Ruggiero FM (2010) Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 48(4):297\u2013310","journal-title":"J Pineal Res"},{"issue":"8","key":"9806_CR176","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1096\/fj.201500118R","volume":"30","author":"KM Holzem","year":"2016","unstructured":"Holzem KM, Vinnakota KC, Ravikumar VK, Madden EJ, Ewald GA, Dikranian K et al (2016) Mitochondrial structure and function are not different between nonfailing donor and end-stage failing human hearts. FASEB J 30(8):2698\u20132707","journal-title":"FASEB J"},{"key":"9806_CR177","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2013.12.029","volume":"68","author":"AM Cordero-Reyes","year":"2014","unstructured":"Cordero-Reyes AM, Gupte AA, Youker KA, Loebe M, Hsueh WA, Torre-Amione G et al (2014) Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function. J Mol Cell Cardiol 68:98\u2013105","journal-title":"J Mol Cell Cardiol"},{"issue":"7586","key":"9806_CR178","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bmj.39104.362951.80","volume":"334","author":"DG Hackam","year":"2007","unstructured":"Hackam DG (2007) Translating animal research into clinical benefit\u2014poor methodological standards in animal studies mean that positive results may not translate to the clinical domain. Br Med J 334(7586):163\u2013164","journal-title":"Br Med J"},{"issue":"9","key":"9806_CR179","first-page":"1636","volume":"7","author":"PC Chandrasekera","year":"2015","unstructured":"Chandrasekera PC, Pippin JJ (2015) The human subject: an integrative animal model for 21(st) century heart failure research. Am J Transl Res 7(9):1636\u20131647","journal-title":"Am J Transl Res"},{"issue":"14","key":"9806_CR180","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2016.07.743","volume":"68","author":"O Wever-Pinzon","year":"2016","unstructured":"Wever-Pinzon O, Drakos SG, McKellar SH, Horne BD, Caine WT, Kfoury AG et al (2016) Cardiac recovery during long-term left ventricular assist device support. J Am Coll Cardiol 68(14):1540\u20131553","journal-title":"J Am Coll Cardiol"},{"key":"9806_CR181","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.09.004","volume":"206","author":"M Dandel","year":"2018","unstructured":"Dandel M, Hetzer R (2018) Recovery of failing hearts by mechanical unloading: pathophysiologic insights and clinical relevance. Am Heart J 206:30\u201350","journal-title":"Am Heart J"},{"issue":"10166","key":"9806_CR182","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","volume":"393","author":"BP Halliday","year":"2019","unstructured":"Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S et al (2019) Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 393(10166):61\u201373","journal-title":"Lancet"},{"issue":"3","key":"9806_CR183","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jacc.2017.06.001","volume":"70","author":"N Uriel","year":"2017","unstructured":"Uriel N, Kim G, Burkhoff D (2017) Myocardial recovery after LVAD implantation a vision or simply an illusion? J Am Coll Cardiol 70(3):355\u2013357","journal-title":"J Am Coll Cardiol"},{"issue":"12A","key":"9806_CR184","doi-asserted-by":"crossref","first-page":"10L","DOI":"10.1016\/j.amjcard.2005.09.060","volume":"96","author":"M Frigerio","year":"2005","unstructured":"Frigerio M, Roubina E (2005) Drugs for left ventricular remodeling in heart failure. Am J Cardiol 96(12A):10L\u201318L","journal-title":"Am J Cardiol"},{"issue":"4","key":"9806_CR185","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.yjmcc.2007.02.002","volume":"42","author":"E Jweied","year":"2007","unstructured":"Jweied E, de Tombe P, Buttrick PM (2007) The use of human cardiac tissue in biophysical research: the risks of translation. J Mol Cell Cardiol 42(4):722\u2013726","journal-title":"J Mol Cell Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09806-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09806-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09806-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T13:28:04Z","timestamp":1596115684000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09806-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":185,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9806"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09806-0","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"17 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}